Pharming Group N.V. Q1 2026 Financial Summary
Business Context and Reporting Period
This Form 6-K filing covers the preliminary unaudited financial results for Pharming Group N.V. for the three months ended March 31, 2026. The company is a global biopharmaceutical firm focused on rare diseases, with key commercial products RUCONEST® (for HAE) and Joenja® (for APDS). The reporting period reflects strategic shifts including the exit from non-U.S. markets for RUCONEST® and significant regulatory milestones for Joenja®.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenue | $72.4 million | $79.1 million | -8% |
| RUCONEST® Revenue | $58.4 million | $68.6 million | -15% |
| Joenja® Revenue | $14.1 million | $10.5 million | +34% |
| Gross Profit | $65.8 million | $70.8 million | -7% |
| Operating Loss | ($4.9) million | ($7.0) million | Improved |
| Net Loss | ($5.2) million | ($14.9) million | Improved |
| Cash from Operations | $2.0 million | $0.2 million | Positive |
| Cash & Equivalents | $171.8 million | $181.1 million (Q4 2025) | -5% |
Debt and Liquidity: Total shareholders' equity stands at $269.0 million. The company holds $171.8 million in cash, cash equivalents, and marketable securities. Convertible bonds total approximately $98.8 million ($93.4 million non-current, $5.4 million current).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 8% year-over-year, primarily driven by a 15% drop in RUCONEST® revenue. This was caused by anticipated inventory drawdowns at U.S. specialty pharmacies (-8% impact) and the strategic exit from non-U.S. markets (-3% impact).
- Joenja® Growth: Joenja® revenue surged 34% due to increased patient uptake in the U.S. (127 patients on paid therapy as of March 31, 2026) and international expansion, particularly in the U.K.
- Profitability Improvement: The net loss narrowed significantly from $14.9 million to $5.2 million. This improvement was aided by a favorable foreign currency gain of $2.4 million (vs. a $2.6 million loss in Q1 2025) and lower tax expenses.
- Operating Expenses: Research and development expenses increased to $25.6 million (from $21.1 million) due to pipeline advancement, while General and Administrative expenses decreased to $15.2 million (from $22.5 million) due to cost reduction initiatives.
Guidance, Outlook, and Risks
- 2026 Guidance: Management reaffirmed total revenue guidance of $405 million to $425 million (8% - 13% growth). Total operating expenses are expected to be between $330 million and $335 million.
- Regulatory Milestones:
- Japan: Joenja® approved for APDS patients aged 4 and older (first global approval for this pediatric age group).
- Europe: Received positive CHMP opinion for APDS; final EC decision expected in Q2 2026.
- U.S. Pediatric: Resubmitted sNDA for highest doses (40mg/50mg) following FDA feedback; plans to submit for lowest doses in summer 2026.
- Pipeline: Enrollment complete for Phase II trials of leniolisib in broader primary immunodeficiencies (PIDs); readouts expected in H2 2026. Pivotal FALCON study for napazimone (KL1333) in mitochondrial disease is ongoing.
- Risks: Revenue variability due to inventory dynamics; regulatory approval timelines; competition in the HAE market; and execution risks associated with pipeline development.
Investor Verification Checklist
- Verify the timeline for the European Commission's final decision on Joenja® marketing authorization.
- Monitor the FDA's response to the resubmitted pediatric sNDA for Joenja® and the summer submission for lower doses.
- Track the impact of the non-U.S. market exit on RUCONEST® revenue stability in subsequent quarters.
- Confirm the progress of the Phase II leniolisib trials in CVID and other PIDs for potential label expansion.
- Review the cash burn rate relative to the $171.8 million cash position to assess runway for pipeline development.